Modulation of β-catenin-mediated TCF-signalling in prostate cancer cell lines by wild-type and mutant p53

Prostate

Volumn 67, Issue 16, 2007, Pages 1751-1760

  Prowald, Alexandra ^a   Cronauer, Marcus V ^b   Von Klot, Christoph ^a   Eilers, Tyark ^a   Rinnab, Ludwig ^c   Herrmann, Thomas ^a   Spindler, Klaus Dieter ^b   Montenarh, Mathias ^d   Jonas, Udo ^a   Burchardt, Martin ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c UNIVERSITY HOSPITAL ULM   (Germany)

^d SAARLAND UNIVERSITY   (Germany)

Author keywords

Beta catenin; p53; Prostate carcinoma; TCF

Indexed keywords

BETA CATENIN; PROTEIN P53; T CELL FACTOR PROTEIN;

ARTICLE; CANCER CELL CULTURE; CANCER STAGING; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; MUTATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REPORTER GENE; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; TRANSCRIPTION INITIATION; WESTERN BLOTTING;

BETA CATENIN; BLOTTING, WESTERN; CELL LINE, TUMOR; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MALE; MUTATION; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TCF TRANSCRIPTION FACTORS; TRANS-ACTIVATION (GENETICS); TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 36849086002     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20660     Document Type: Article

References (36)

1. Hsing A, Tsao L, Devesa S. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 2000;85:60-67.
2. Isaacs JT. Molecular markers for prostate cancer metastasis. Developing diagnostic methods for predicting the aggressiveness of prostate cancer. Am J Pathol 1997;150:51511-51521.
3. Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B, Clevers H. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997;275(5307):1784- 1787.
4. Truica CI, Byers S, Gelmann EP. Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res 2000;60(17):4709- 4713.
5. Morin PJ. Beta-catenin signaling and cancer. Bioessays 1999;21(12):1021-1030.
6. Muller-Tidow C, Steffen B, Cauvet T, Tickenbrock L, Ji P, Diederichs S, Sargin B, Kohler G, Stelljes M, Puccetti E, Ruthardt M, deVos S, Hiebert SW, Koeffler HP, Berdel WE, Serve H. Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol Cell Biol 2004;24(7):2890-2904.
7. Ginsberg D, Mechta F, Yaniv M, Oren M. Wild-type p53 can down-modulate the activity of various promoters. Proc Natl Acad Sci USA 1991;88:9979-9983.
8. Bookstein R, Macgrogan D, Hilsenbeck SG, Sharkey F, Allred DC. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 1993;53:3369-3373.
9. Kunimi K, Amano T, Uchibayashi T. Point mutation of the p53 gene is an infrequent event in untreated prostate cancer. Cancer Detect Prev 1996;20:218-222.
10. Milner J, Medcalf EA. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell 1991;65(5):765-774.
11. Levina E, Oren M, Ben-Ze'ev A. Downregulation of beta-catenin by p53 involves changes in the rate of beta-catenin phosphorylation and Axin dynamics. Oncogene 2004;23(25):4444-4453.
12. Rother K, Johne C, Spiesbach K, Haugwitz U, Tschop K, Wasner M, Klein-Hitpass L, Moroy T, Mossner J, Engeland K. Identification of Tcf-4 as a transcriptional target of p53 signalling. Oncogene 2004;23(19):3376-3384.
13. Tomkova K, Belkhiri A, El-Rifai W, Zaika AI. p73 isoforms can induce T-cell factor-dependent transcription in gastrointestinal cells. Cancer Res 2004;64(18):6390-6393.
14. Shenk JL, Fisher CJ, Chen SY, Zhou XF, Tillman K, Shemshedini L. p53 represses androgen-induced transactivation of prostate-specific antigen by disrupting hAR amino- to carboxyl-terminal interaction. J Biol Chem 2001;276(42):38472-38479.
15. Cronauer MV, Schulz WA, Burchardt T, Ackermann R, Burchardt M. Inhibition of p53 function diminishes androgen receptor-mediated signalling in prostate cancer cell lines. Oncogene 2004;23(20):3541-3549.
16. Sengupta S, Wasylyk B. Physiological and pathological consequences of the interactions of the p53 tumor suppressor with the glucocorticoid, androgen, and estrogen receptors. Ann NY Acad Sci 2004;1024:54-71.
17. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 1994;265:346-355.
18. Bullock AN, Henckel J, DeDecker BS, Johnson CM, Nikolova PV, Proctor MR, Lane DP, Fersht AR. Thermodynamic stability of wild-type and mutant p53 core domain. Proc Natl Acad Sci USA 1997;94(26):14338-14342.
19. Cronauer MV, Schulz WA, Ackermann R, Burchardt M. Effects of WNT/beta-catenin pathway activation on signalling through T-cell factor and androgen receptor in prostate cancer cell lines. Int J Oncol 2005;26(4):1033-1040.
20. Schuster N, Prowald A, Schneider E, Scheidtmann K-H, Montenarh M. Regulation of p53 mediated transactivation by the β-subunit of protein kinase CK2. FEBS Lett 1999;447:160-166.
21. Schuster N, Goetz C, Faust M, Schneider E, Prowald A, Jungbluth A, Montenarh M. Wild-Type p53 inhibits protein kinase CK2 activity. J Cell Biochem 2001;81:172-183.
22. Shaulian E, Zauberman A, Ginsberg D, Oren M. Identification of a minimal transforming domain of p53: Negative dominance through abrogation of sequence-specific DNA binding. Mol Cell Biol 1992;12(12):5581-5592.
23. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ, Lucia MS. Molecular characterization of human prostate carcinoma cell lines. Prostate 2003;57(3):205-225.
24. Kawaguchi T, Kato S, Otsuka K, Watanabe G, Kumabe T, Tominaga T, Yoshimoto T, Ishioka C. The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library. Oncogene 2005;24(46):6976-6981.
25. Liu J, Wu X, Mitchell B, Kintner C, Ding S, Schultz PG. A small-molecule agonist of the Wnt signalling pathway. Angew Chem Int Ed Engl 2004;44(13):1987-1990.
26. Cagatay T, Ozturk M. p53 mutation as a source of aberrant β-catenin accumulation in cancer cells. Oncogene 2002;21:7971-7980.
27. Sadot E, Geiger B, Oren M, Ben-Ze'ev A. Down-regulation of beta-catenin by activated p53. Mol Cell Biol 2001;21(20):6768-6781.
28. Hupp TR, Meek DW, Midgley CA, Lane DP. Regulation of the specific DNA binding function of p53. Cell 1992;71(5):875-886.
29. Subler MA, Martin DW, Deb S. Overlapping domains on the p53 protein regulate its transcriptional activation and repression functions. Oncogene 1994;9(5):1351-1359.
30. Hong TM, Chen JJ, Peck K, Yang PC, Wu CW. p53 amino acids 339-346 represent the minimal p53 repression domain. J Biol Chem 2001;276(2):1510-1515.
31. Hall SR, Campbell LE, Meek DW. Phosphorylation of p53 at the casein kinase II site selectively regulates p53-dependent transcriptional repression but not transactivation. Nucleic Acids Res 1996;24(6):1119-1126.
32. Cronauer MV, Schulz WA, Burchardt T, Anastasiadis AG, De La Taille A, Ackermann R, Burchardt M. The androgen receptor in hormone-refractory prostate cancer: Relevance of different mechanisms of androgen receptor signaling. Int J Oncol 2003;23:1095-1102.
33. Hamroun D, Kato S, Ishioka C, Claustres M, Beroud C, Soussi T. The UMD TP53 database and website: Update and revisions. Hum Mutat 2006;27(1):14-20.
34. Nesslinger NJ, Shi XB, deVere White RW. Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53. Cancer Res 2003;63(9):2228-2233.
35. Gurova KV, Roklin OW, Krivokrysenko VI, Chumakov PM, Cohen MB, Feinstein E, Gudkov AV. Expression of prostate specific antigen (PSA) is negatively regulated by p53. Oncogene 2002;21(1):153-157.
36. Miller CW, Chumakov A, Said J, Chen DL, Aslo A, Koeffler HP. Mutant p53 proteins have diverse intracellular abilities to oligomerize and activate transcription. Oncogene 1993; 8(7):1815-1824.